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ABSTRACT 
The hypoxia inducible factor (HIF) system 
orchestrates cellular responses to hypoxia in 
animals. HIF is an α/β-heterodimeric transcription 
factor that regulates the expression of hundreds of 
genes in a tissue context dependent manner. The 
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major hypoxia-sensing component of the HIF 
system involves oxygen-dependent catalysis by 
the HIF hydroxylases; in humans there are three 
HIF prolyl hydroxylases (PHD1-3) and an 
asparaginyl hydroxylase (FIH). PHD catalysis 
regulates HIFα levels and FIH catalysis regulates 
HIF activity. How differences in HIFα 
hydroxylation status relate to variations in the 
induction of specific HIF target gene transcription 
is unknown. We report studies using small 
molecule HIF hydroxylases inhibitors that 
investigate the extent to which HIF target gene 
expression is induced by PHD or FIH inhibition. 
The results reveal substantial differences in the 
role of prolyl- and asparaginyl-hydroxylation in 
regulating hypoxia responsive genes in cells. PHD 
inhibitors with different structural scaffolds 
behave similarly. Under the tested conditions, a 
broad-spectrum 2OG dioxygenase inhibitor is a 
better mimic of the overall transcriptional response 
to hypoxia than the selective PHD inhibitors, 
consistent with an important role for FIH in the 
hypoxic transcriptional response. Indeed, 
combined application of selective PHD and FIH 
inhibitors resulted in the transcriptional induction 
of a subset of genes not fully responsive to PHD 
inhibition alone. Thus, for the therapeutic 
regulation of HIF target genes, it is important to 
consider both PHD and FIH activity, and in the 
case of some sets of target genes, simultaneous 
inhibition of the PHDs and FIH catalysis may be 
preferable. 
 
INTRODUCTION 
In animals, the cellular response to hypoxia, i.e. 
limiting oxygen availability, is predominantly 
orchestrated by the hypoxia-inducible transcription 
factors (HIFs) which work over a time course of 
hours to days to adapt cells and tissues to limiting 
oxygen availability (for review, see (1)). The α/β-
heterodimeric HIF transcription factors can 
directly upregulate hundreds of genes, including 
those encoding for erythropoietin (EPO) and 
vascular endothelial growth factor (VEGF) (for 
review, see (1)). Thus, therapeutic manipulation of 
the HIF system has substantial medicinal potential, 
e.g. by promoting EPO production for the 
treatment of anaemia (2), or by downregulating 
VEGF production in tumours (3). To date, the only 
validated cellular oxygen sensing mechanism in 
humans for the HIF hypoxia sensing system is 
provided by a set of 2-oxoglutarate (2OG) and 
ferrous iron dependent dioxygenases. The three 
human isoforms of the HIF prolyl-hydroxylases 
(PHD1-3) signal for HIFα degradation by 
catalysing the trans-4-proyl hydroxylation of 
HIF1α and HIF2α isoforms at either, or both, of 
two specific sites in the N- or C-terminal oxygen-
dependent degradation domains (NODD and 
CODD, respectively) (4-8). Increases in HIF1α 
and HIF2α levels are associated with the 
upregulation of different sets of HIF target genes, 
for example, HIF1α is principally associated with 
glycolytic genes (such as PGK1, HK2 and LDHA) 
upregulation (9) and HIF2α with EPO 
upregulation (10,11). HIFα prolyl-hydroxylation 
in the NODD and CODD regions serves as the 
recognition signal for the von-Hippel Lindau 
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protein (pVHL), the targeting component of an 
ubiquitin E3 ligase complex (6-8,12). Thus, HIFα 
isoforms are degraded in an oxygen-dependent 
manner by the ubiquitin-proteasome system. A 
second type of HIFα oxidation (asparaginyl-
hydroxylation) occurs in the C-terminal 
transcriptional activation domain (CTAD) of HIFα 
isoforms, as catalysed by factor inhibiting HIF 
(FIH); this hydroxylation blocks the interaction 
between HIFα and the p300/CBP family of 
transcriptional co-activator proteins (13-18). The 
sensitivity of HIF hydroxylase catalysis to oxygen 
availability is directly coupled to the stabilisation 
and activation of HIF. Thus, the HIF hydroxylases 
act as cellular oxygen sensors - with the PHD 
catalysis regulating HIF levels, and FIH catalysis 
regulating HIF activity (Fig. 1A).  
The HIF system regulates the expression 
of many genes by directly upregulating their 
transcription (19,20) and has the potential to 
indirectly regulate many other genes. The HIF 
system is therefore capable of profound cellular 
reprogramming. 2OG dioxygenases, such as the 
PHDs and FIH are amenable to inhibition by small 
molecules, and PHD inhibitors (PHIs) are 
currently in advanced stages of clinical studies for 
the treatment of anaemia through the HIF-
mediated upregulation of EPO (2,21-23). The 
success of such inhibitors will likely in part be 
dependent on their ability to selectively upregulate 
EPO gene expression in a sufficiently safe 
manner, i.e. with low toxicity and side effects. The 
extent to which selective transcription of EPO (for 
example) can be achieved, and whether or not the 
concurrent upregulation of the other HIF target 
genes is therapeutically desirable, remains to be 
determined.  
Distinct sets of HIF target genes are 
expressed in different cells/tissues, in a context-
dependent manner (24).The mechanism(s) by 
which context-dependent HIF regulation of 
expression is achieved are of major clinical and 
basic science interest. In the latter case, this 
question is applicable to any pleiotropic 
transcriptional regulation system. Understanding 
and exploiting the chemical details of such context 
dependent regulation of expression is a major 
challenge in contemporary molecular biology. 
Because of the strong induction of active HIFα 
isoforms in response to changes in atmospheric 
oxygen availability (hypoxia), it may be that the 
HIF system is a particularly good model for 
addressing such questions.  
Although the precise regulatory 
mechanisms underlying the regulation of specific 
sets of HIF target genes are likely extremely 
complex from a chemical perspective (e.g. 
involving the combinatorial modifications on the 
histone H3 N-terminal tail), some such 
mechanisms are likely to be more important than 
others, at least in terms of the physiological 
hypoxic response. In this regard, the differential 
roles of the PHDs and FIH are of particular 
interest; the available evidence is that PHD 
activity is more sensitive to hypoxia than that of 
FIH, as supported by studies with both cellular and 
isolated enzymes (25-27). Moreover, there are few 
studies on how the PHDs and FIH might 
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differentially affect transcription of specific genes 
(28-31). Such studies are of interest with regard to 
the therapeutic manipulation of HIF target genes, 
i.e. ‘dual action’ PHD and FIH inhibition may be 
desirable in some, but not other, cases. More 
generally, there is the question of how well small 
molecules targeting the HIF hydroxylases mimic 
physiological hypoxia.  
Here, we report studies investigating the 
extent to which HIF target gene expression is 
regulated by the PHDs and FIH. Our results imply 
that the role of FIH in regulating HIF-responsive 
gene expression varies substantially, both in terms 
of the HIF target genes in the same cell and the 
same HIF target genes in different cells. The 
results also revealed the unexpected result that 
broad-spectrum 2OG dioxygenase inhibitor is a 
better mimic of the transcriptional response to 
hypoxia than selective PHD inhibitors, at least in 
the studied cell line. 
 
RESULTS 
DMOG better mimics the transcriptional response 
to hypoxia than selective PHD inhibitors in MCF-
7 cells - We used high-throughput RNA 
sequencing (RNA-seq) to investigate the cellular 
transcriptional response to hypoxia as well as the 
effects of three small-molecule inhibitors that have 
been reported to be selective (at least over some, 
but likely not all, other human 2OG oxygenases) 
for the PHDs (FG2216/BIQ, IOX2 and BNS; 
collectively referred to as the PHIs) or a broad 
spectrum 2-oxoglutarate (2OG) analogue, 
dimethyloxalylglycine (DMOG) (Fig. 1B). 
DMOG is a prodrug form of N-oxalylglycine 
(NOG) which has been extensively used as a 2OG 
dioxygenase inhibitor in cellular and animal 
studies (27,32,33). The three PHD inhibitors were 
selected because one of them has been used in 
clinical trial of anaemia (BIQ/FG2216) (34), one 
has been profiled in some detail for selectivity and 
potency (IOX2) (35,36) and another (BNS) has a 
substantially different heteroaromatic structure 
(37). In vitro hydroxylation assays for PHD1-3 
indicate that the PHIs (BIQ and IOX2) and NOG 
potently inhibit all three of the human PHDs (Fig. 
1C). In our cell-based studies, we tested human 
breast cancer MCF-7 cells treated under normoxia, 
hypoxia (0.5% O2), or with the small molecule 
inhibitors (DMOG, IOX2, BNS and BIQ). MCF-7 
cells were selected in part because they are known 
to upregulate both the HIF1α and HIF2α in 
response to hypoxia (38). ‘Optimal’ concentrations 
of the small molecule inhibitors required for the 
induction of both HIF1α and HIF2α (to 
approximately the same level detected under 0.5% 
O2) were first determined by immunoblotting (Fig. 
1D). We then treated the MCF-7 cells with the 
experimentally determined concentrations of 250 
µM IOX2, 500 µM BIQ, 250 µM BNS, 1 mM 
DMOG or 0.5% O2 for 16 h before profiling for 
genome-wide gene expression changes using 
RNA-seq (n=2 per condition). 
 Differential expression analysis confirmed 
clear hypoxia-induced changes in our RNA-seq 
data set with the transcription of 1081 genes being 
identified as being upregulated in hypoxia 
compared with normoxia (Supplemental Data). 
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This set of genes was enriched for KEGG 
pathways known to be involved in the cellular 
response to hypoxia including glycolysis / 
gluconeogenesis (hypergeometric test; fold 
enrichment = 5.22, FDR = 1 x 10-6). Further, we 
reproduced the induction of genes proposed to 
reflect a core hypoxic ‘signature’ (39), namely 
ADM, AK3L1, BNIP3, CA9, CCNG, ENO1, HK2, 
LDHA, PFKFB3, PGK1, SLC2A1 and VEGFA (all 
with fold changes > 2 and false discovery rate 
(FDR) < 0.05).  
We then investigated the extent to which 
the PHIs mimicked the transcriptional response to 
hypoxia. Overall, the different types of selective 
PHIs all displayed similar transcriptional profiles 
to each other; these were clearly distinct to those 
observed for normoxia (Fig. 2A). Notably, we 
observed that the transcriptional response to the 
broad-spectrum inhibitor DMOG was more similar 
to the hypoxic response than it was for any of the 
selective PHI (Fig. 2A). These observations were 
supported by studies in which we restricted the 
analyses to those genes that were regulated by 
hypoxia (Fig. 2B). Hierarchical clustering of 
hypoxia-regulated genes revealed the presence of 
four clusters (Fig. 2B); we assigned each gene to 
one of four clusters using k-means clustering 
(k=4). These clusters represent: those genes that 
were down-regulated in hypoxia and DMOG, but 
to a lesser extent by the PHI (cluster 1), those that 
were upregulated by hypoxia, DMOG and the PHI 
(albeit to a varying degree) (cluster 2), those that 
were upregulated by hypoxia and DMOG, but to a 
lesser extent by the PHI (cluster 3), and those that 
were only upregulated by hypoxia (cluster 4). The 
identification of clusters that represent genes 
regulated predominantly by hypoxia and DMOG 
as opposed to the PHI is manifested as a greater 
overlap of differentially expressed genes between 
these conditions when compared with normoxia 
(Fig. 2C). Indeed, DMOG regulated ~50% of 
hypoxia-regulated genes compared with ~35%, 
~35% and ~25% for BIQ, IOX2 and BNS, 
respectively. This pattern is not due, at least 
solely, to temporal or magnitude differences in the 
induction of HIF1α/HIF2α between hypoxia and 
PHI, because the stablisation of both HIFα 
proteins after treatment by IOX2 (used as a 
representative selective PHD inhibitor) was more 
rapid and of greater magnitude when compared 
with 0.5% O2 treatment over a 16-hour period 
(Fig. 2D). Notably, the levels of FIH-catalysed 
HIF1α CAD hydroxylation under 0.5% O2 
suggested that FIH activity was partially inhibited 
by hypoxia under the tested conditions consistent 
with FIH being more active than the PHDs under 
hypoxia (27), whereas CAD hydroxylation was 
not inhibited with IOX2 treatment alone.  
Given the central role of HIF in regulating 
the transcriptional response to physiological 
hypoxia, we were interested in investigating 
potential differences between our identified gene 
clusters (Fig.2B) and their HIF dependency. We 
used reported HIF1α and HIF2α ChIP-seq and 
siRNA data (40,41) to assess the extent to which 
genes in each cluster were regulated by HIF. 
Clusters that contained genes up-regulated in 
hypoxia (i.e. clusters 2, 3 and 4) were significantly 
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enriched for HIF1α and HIF2α binding (Fig. 2E). 
Those specifically up-regulated by hypoxia and 
DMOG (cluster 3) showed the strongest evidence 
for direct targetting by HIF (HIF1α overlap=30%, 
HIF2α overlap=22%). Similar to HIF binding, 
clusters that contained genes up-regulated in 
hypoxia were significantly enriched for genes 
down-regulated by HIF1α siRNA treatment in 
hypoxia (Fig 2F; left). HIF2α siRNA treatment in 
hypoxia had a smaller effect on the regulation of 
hypoxia-inducible genes (Fig. 2F; middle) where 
a combination of the two had an effect more 
comparable to HIF1α siRNA alone (Fig. 2F; 
right). Using gene set enrichment analysis (GSEA) 
and the reported HIF ChIP-seq data, we observed 
a robust association between the HIFα binding and 
the loci of genes upregulated by either hypoxia, 
DMOG or the PHIs (data not shown).  
 Together, these results suggest that, at 
least under the tested conditions, DMOG better 
mimics the transcriptional response to cellular 
hypoxia than the (tested) selective PHI. This 
difference may be due to increased transcriptional 
activity of HIF1α and HIF2α due to the 
‘additional’ inhibition of FIH by hypoxia and 
DMOG compared to the selective PHI alone. 
 
Combined PHD and FIH inhibition is required for 
optimal induction of a subset of hypoxia-inducible 
genes – Given the greater inhibition of FIH by 
0.5% O2 and DMOG than by the PHI (Fig. 1D and 
2D), we proposed that FIH inhibition could 
explain the differences in transcriptional 
regulation by hypoxia/DMOG versus the PHI. To 
test the role of FIH, we used short interfering RNA 
(siRNA) to downregulate FIH production, as well 
as the dimethyl ester of a selective FIH small 
molecule inhibitor, N-oxalyl-D-phenylalanine 
(DM-NOFD (42)) to inhibit FIH activity. NOFD 
showed lack of in vitro inhibitory activities against 
a panel of Jumonji-C containing proteins KDM3A, 
KDM4E and KDM6B (IC50 values > 20 µM, data 
not shown). We found that in MCF-7 cells, FIH 
siRNA treatment did not completely block HIF1α 
CAD hydroxylation despite reduction of FIH to 
below the limit of detection at the protein level 
(Fig. 3A) and >80% reduction at the mRNA level 
(data not shown). Thus, the residual FIH, not 
detected by Western blotting, is likely able to 
hydroxylate the stabilised HIF1α proteins over 
time. Inhibition of HIF1α CAD hydroxylation was 
more efficiently achieved by the use of DM-
NOFD, which reduced HIF1α CAD hydroxylation 
to the level comparable to that observed under 
0.5% O2 (Fig. 3A). Complete ablation of FIH 
activity was achieved by combined DM-NOFD 
and FIH siRNA treatment (Fig. 3A).  
 Using microarrays, we then assessed the 
ability of dual inhibition of the PHDs and FIH to 
modulate hypoxia-regulated genes. Whilst there 
were some variations between the RNA-seq and 
microarray analysis for hypoxia, DMOG and 
IOX2 conditions (Fig. 3B-I), we identified (and 
verified by qRT-PCR) candidate genes: (i) that 
were induced by PHD inhibition to levels 
comparable to those observed in hypoxia without 
FIH inhibition (e.g., BNIP3, LDHA, VLDLR and 
PPFIA4, Fig. 3H, 4A), (ii) those that required both 
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PHD inhibition and additional FIH inhibition for 
complete induction (e.g., CA9, ADM, EGLN3 and 
HK2, Fig. 3I, 4B) and (iii) those that could not be 
induced to levels comparable to hypoxia 
regardless of PHD and FIH inhibition (e.g. SOX9 
and ANKRD37, Fig. 3I, 4C). Taken together, these 
results indicate that different genes upregulated by 
hypoxia have different requirements for inhibition 
of the PHDs and FIH for detectable transcriptional 
activation. 
 
Some hypoxia-inducible genes require more than 
the inhibition of the PHDs and FIH for 
transcriptional activation in MCF-7 cells – From 
the gene expression profiling studies, we observed 
that SOX9 and ANKRD37 can be upregulated by 
hypoxia (and to a certain degree by DMOG), but 
are not optimally upregulated by both PHD and 
FIH inhibition. Given that to this point our 
investigations had mostly focused on a single time 
point (16 h), we investigated the possibility that 
these genes may be induced to a level comparable 
to those in hypoxia at an earlier time point (i.e. 
less than 16 h). qRT-PCR analyses reveal that 
SOX9 remained unaffected by IOX2 treatment or 
IOX2 and DM-NOFD treatment over a period of 
up to 16 h (Fig. 4D, left). Similarly, although 
induction of ANKRD37 gene expression was 
observed with IOX2 (and combined IOX2 and 
DM-NOFD) treatment, it did not reach the level of 
induction observed under hypoxia over a period of 
up to 16 h) (Fig. 4D, right), consistent with the 
previous observations (Fig. 4C). These results 
demonstrate that in cultured MCF-7 cells, the 
incomplete upregulation of a subset of hypoxia 
upregulated genes (such as SOX9 and ANKRD37) 
by combined PHD and FIH inhibition is not due to 
time-dependent effects.  
 
Requirements for PHDs and FIH for induction of 
hypoxia upregulated genes are cell-type dependent 
– To explore whether hypoxia upregulated genes 
are differentially regulated by the PHDs and FIH 
in a similar manner across different cell-types, we 
then studied the effect of IOX2 (i.e. a selective 
PHD inhibitor) and combined IOX2 and DM-
NOFD treatment (i.e. combined PHD and FIH 
inhibition) on selected genes in U2OS, Hep3B and 
HeLa cells (Fig.5A). EGLN3 induction in these 
cell lines requires the inhibition of both the PHDs 
and FIH to be induced to at least the level seen 
under hypoxia, as we previously observed in 
MCF-7 cells. This is also the case for CA9 
induction in Hep3B, but not in U2OS and HeLa 
cells, whereby the induction of CA9 by IOX2 
alone is comparable to that by hypoxia (although 
the inhibition of FIH enhances IOX2 mediated 
induction further). Genes previously observed in 
MCF-7 cells to be ‘fully’ (relative to hypoxia) 
induced by IOX2 alone (such as BNIP3 and 
LDHA) were consistently induced by IOX2 to 
levels comparable to hypoxia in all the tested cell 
lines. SOX9, a hypoxia-induced gene shown to be 
non-responsive to the inhibition of PHDs and FIH 
in MCF-7 cells, is not substantially induced by 
hypoxia in U2OS and Hep3B cells (fold-change < 
2), but is hypoxia-induced and responsive to PHD 
and FIH inhibition in HeLa cells. ANKRD37, 
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another hypoxic-induced gene that is upregulated 
by IOX2 and DM-NOFD treatment in MCF-7 
cells albeit at levels lower than those in hypoxia, 
can be upregulated in U2OS, Hep3B and HeLa 
cells to levels higher or similar to hypoxia 
treatment.  
 
DISCUSSION 
Given the links between the HIF-mediated 
oxygen sensing and response system and multiple 
pathological conditions, it is of interest to 
investigate the extent to which the cellular 
transcriptional response to hypoxia can be 
mimicked by small molecule inhibitors. We used 
high-throughput RNA sequencing and microarray 
gene expression profiling to study the regulation 
of hypoxia-responsive genes and their dependency 
on PHD and FIH inhibition by selective small 
molecule inhibitors. Although genome wide 
expression profiling to compare the effects of 
DMOG to hypoxia has previously been carried out 
on the HIF system (43), to our knowledge this is 
the first report of genome wide expression 
profiling using selective small molecule inhibitors 
of the HIF hydroxylases. These results provide 
insights into the effects of PHI on HIF target gene 
expression in vivo, which may be useful in terms 
of interpreting the physiological effects of PHI 
presently in trials for the treatment of anaemia 
(2,21-23). More generally, the results suggest that 
the use of small molecules targeting more than one 
regulatory element in order to control the activity 
of pleiotropic transcription factors has 
considerable potential. 
The results reveal that inhibition of the PHDs 
alone using selective compounds is capable of 
significantly upregulating a substantial subset of 
hypoxia-regulated genes. Notably, however, at 
least in the studied cells types, the overall 
transcriptional response to hypoxia is better 
mimicked by the broad spectrum 2OG 
dioxygenase inhibitor DMOG, which likely 
inhibits multiple types of 2OG oxygenases 
(32,33), than by the selective PHI.  
The degree of induction of specific genes 
varies across the different cell types in response to 
hypoxia and the different inhibitors (Fig.5). 
Although many factors at the post-transcriptional 
level are protentially involved, in part this 
observation may reflect the differing levels of HIF 
proteins and/or the HIF hydroxylases (FIH, PHD1-
3) in the different cell lines (Fig. 5B). The levels 
of some of the components of the HIF system also 
likely vary over the tiemescales of the analyses; 
PHD2, and in particular PHD3, are strongly 
upregulated by hypoxia / HIF (5). Other factors 
that may affect expression levels of HIF target 
genes include variations in the cellular localisation 
dynamics of the HIF isoforms (44) and variations 
in the levels of other 2OG oxygenases, incuding 
the Jumonji C (JmjC) domain-containing histone 
N-methyl lysine demethylases (KDMs), some of 
which are regulated by hypoxia / HIF (20,45,46). 
It is also important to note that the PHIs are likely 
to have different levels of selectivity for the PHD 
isoforms in cells and may, to varying extent, 
inhibit other members of the 2OG dioxygenase 
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family (e.g. BIQ has been reported to inhibit the 
fat mass and obesity protein FTO in vitro (47)). 
There may also be differences in the precise 
mode of action of PHIs that could affect their 
activities, e.g. some inhibitors may compete with 
HIFα at the PHD active site and others not (35). 
Nevertheless, despite the differences in their 
structures, all three of the selective PHD inhibitors 
used in this study showed comparable effects on 
gene expression profiles, implying that there is a 
subset of hypoxia-responsive genes which can be 
regulated principally through the inhibition of the 
PHDs, even in the presence of fully active FIH.  
Analyses of 19 gene expression datasets from 
14 different cell lines have revealed a relatively 
small set of genes that are upregulated consistently 
and substantially by hypoxia or hypoxia mimetics, 
consistent with the proposal of a core set of 
hypoxically upregulated genes both in different 
human cell types (24) and in other animals (48). 
Our overall results are consistent with an 
important, but variable and context dependent role 
for FIH in the regulation of HIF target gene 
expression, i.e. the upregulation of some HIF 
target genes is substantially more dependent on 
inhibition of FIH catalysed hydroxylation than 
others. Indeed, previous PHD and FIH silencing 
studies by RNA interference have shown that 
hypoxia upregulated genes have different 
requirements for the PHDs and FIH to be 
transcriptionally activated, and may reflect the 
differential regulation of genes across an oxygen 
gradient (28). This dependency is context-
dependent, and may reflect differences in the 
levels of the PHDs, FIH and HIFα isoforms (and 
other factors as described above) in different cell-
types relating to their biological roles in regulating 
the hypoxic response under different oxygen 
tensions in vivo (27,31,38).  
At present the reasons for the differences in 
the variable extents of the involvement of FIH in 
HIF target gene expression are largely unknown. 
HIFα CTAD hydroxylation disrupts the interaction 
between the CBP/p300 cysteine/histidine-rich 1 
(CH1) domains and HIFα CTAD (30). However, 
HIFα has another site of interaction with 
CBP/p300 cysteine/histidine-rich 3 (CH3) domain, 
i.e. via its N-terminal transactivation domain 
(NTAD) (49) which may influence the extent of 
FIH involvement in HIF target gene expression. 
CBP/p300 are transcriptionally activating proteins 
in part because they contain histone lysine N-
acetyl transferase and bromodomain domains (50); 
one possibility is that in the case of some HIF 
target genes, the corresponding histone lysine N-
acetylation is more limiting for transcriptional 
upregulation than is a decrease in FIH activity. 
The results also clearly imply that in the cases of 
some genes, factors other than PHD/FIH catalysis 
can limit expression. 
An important finding arising from the results 
is that at least in MCF-7 cells, certain genes that 
are strongly upregulated in hypoxia cannot be 
similarly induced by the inhibition of both the 
PHDs and FIH, for example SOX9 and ANKRD37 
(Fig. 4C-D). Both of these genes have been 
previously described as HIF target genes (51,52) 
and are reported to contain HIF1α and/or HIF2α 
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binding sites within the viscinity of their gene loci 
in the same cell line (MCF-7) used in our studies 
(40). We demonstrated that the reduced or lack of 
induction by PHD inhibitor and FIH inhibitor in 
our studies in MCF-7 cells is not due to temporal 
effects of the inhibitors, as judged by the levels of 
HIFα, HIF1α CAD hydroxylation and the 
induction of the genes across different time points. 
These observations thus point towards another 
form of oxygen-dependent transcriptional 
regulation via an additional factor(s), potentially 
including 2OG dioxygenases, that may be HIF-
dependent or independent, as indicated by the 
observation that they are induced by the broad 
spectrum 2OG dioxygenase inhibitor DMOG. 
Such regulation may be direct, e.g. by oxygen 
dependent regulation of histone demethylation 
(e.g. via modulation of JmjC KDM activity), or be 
indirect. In the latter regard it is notable that some 
2OG dioxygenases are themselves hypoxically 
regulated, including PHDs 2 and 3 and some, but 
not all, of the 2OG dependent JmjC histone 
demethylases (20,45,46,53). The use of chemical 
probes selective for 2OG dioxygenases and/or 
gene knockdown studies targeting members of the 
2OG-dependent dioxygenase family other than the 
PHDs and FIH may provide insights into how 
these additional factor(s) play roles in the hypoxia-
mediated upregulation of these genes. 
The 2OG-dependent dioxygenase enzymes all 
require oxygen to function; however, other than 
the HIF hydroxylases, there is no evidence that 
they play direct roles as hypoxia sensors in animal 
cells. A recent in vitro study reports that, like 
PHD2, a human histone demethylase KDM4E 
(which is also a member of the 2OG-oxygenase) 
reacts slowly with oxygen (54), a proposed 
characteristic of hypoxia sensors which has been 
observed with PHD2 (55) and to much lesser 
extent FIH (56). Thus, there is at least potential for 
the JmjC histone demethylases and other 2OG 
dioxygenases to act as hypoxia sensors (53,56). It 
is also likely that 2OG dioxygenases, including the 
JmjC histone demethylases, along with multiple 
other factors, play roles in determining the set of 
HIF target genes that are hypoxically regulated. It 
should be noted that demonstration of the oxygen 
dependence of in cell hydroxylation (e.g. as occurs 
for HIF hydroxylation) is substantially easier than 
demethylation, since ‘simple’ post-translational 
hydroxylation does not require a prior post-
translational modification as does demethylation. 
Furthermore, hydroxylation is either present or 
absent on a given amino acid, whereas a single 
residue can show different methylation statuses. 
Along with the complexity of histone 
modifications (in particular for histone H3), this 
renders the antibody based interpretation of 
changes in hydroxylation modifications 
substantially easier (at least in our experience) 
than demethylation (57). Our analyses of reported 
H3K4me3 ChIP-seq dataset in MCF-7 (41), 
however, did not reveal any identifiable difference 
between hypoxia-upregulated genes which are 
non-responsive to PHD and FIH inhibition (such 
as SOX9) and genes that are (such as CA9 or 
BNIP3) (data not shown). Hence, a detailed study 
of the histone methylation status (other than 
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H3K4me3) at the loci of hypoxia induced genes 
which are non-responsive to PHD and FIH 
inhibition is of interest with respect to identifying 
dioxygenases other than the HIF hydroxylases 
involved in hypoxic sensing, but this is beyond the 
scope of the current investigation.  
Overall, our studies indicate that there are 
minimally three subsets of hypoxia-upregulated 
HIF target genes based on their requirement for 
PHDs and/or FIH inhibition in a context-
dependent manner, i.e. (i) those apparently 
requiring only the inhibition of the PHDs for 
hypoxic upregulation, (ii) those requiring the 
inhibition of the PHDs and FIH for hypoxic 
upregulation, and (iii) those that are not 
substantially, or only partially induced by the 
inhibition of both the PHDs and FIH in the 
hypoxia response. In the case of the latter genes, 
there is the possibility that other 2OG 
dioxygenases are involved in their transcriptional 
regulation, potentially in a directly hypoxia 
regulated manner. However, there are many other 
possibilities for regulation of these genes, 
including by chromatin (histone or DNA 
modifications) and other post-transcriptional 
processes that affect RNA levels.  
Perhaps most notably, the results suggest that 
the ‘semi-rational’ (i.e. based on knowledge of the 
extensive chemical complexity of the regulation of 
expression in higher organisms) targeting of 
combinations of regulatory processes in order to 
manipulate the transcription of genes controlled by 
pleiotropic transcription factors (e.g. HIF) will be 
an interesting avenue for therapeutic benefit. 
 
EXPERIMENTAL PROCEDURES 
Cell culture and treatment 
Human cell lines (MCF-7, Hep3B and U2OS) 
were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, D6546-500ML; Sigma Aldrich) 
each supplemented with 10% fetal bovine serum 
(F7524-500ML; Sigma Aldrich), 2 mM L-
glutamine (G7513-100ML; Sigma Aldrich), 50 
units/ml of penicillin, and 50 µg/ml of 
streptomycin (P0781-100ML; Sigma Aldrich). 
MCF-7 cell line was from the American Type 
Culture Collection (ATCC), Hep3B cell line was 
from the European Collection of Cell Cultures 
(ECACC) (12). U2OS cell line was a gift from S. 
Galey (ICRF Clare Hall Laboratories, United 
Kingdom). Cells were treated either with DMSO 
(control) or compounds (dissolved in DMSO) and 
added directly into the cell culture medium to the 
desired final concentration as previously described 
(27,35). For hypoxia (0.5% O2) treatment, cells 
were seeded at least 24 h prior to being incubated 
for 16 h in an In vivo2 400 hypoxic workstation 
(Ruskin technologies, Bridgend, United 
Kingdom).  
 
Immunoblotting 
Cell extracts were prepared using urea/SDS buffer 
(6.7 M urea, 10 mM Tris-HCl pH 6.8, 10% 
glycerol and 1% SDS) and processed for 
immunoblotting as previously described (27). The 
following primary antibodies were used for 
immunoblotting: mouse monoclonal HIF1α 
antibody clone 54 (610958, BD Transduction 
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Laboratories), mouse monoclonal HIF2α antibody 
clone 190b (58), mouse monoclonal HIF1α 
hydroxy-Asn803 antibody (a kind gift from Dr M. 
K. Lee, Republic of Korea (59)), rabbit polyclonal 
PHD1 antibody (38), mouse monoclonal PHD2 
antibody clone 76a (38), mouse monoclonal PHD3 
antibody clone 188e (38), mouse monoclonal FIH 
antibody clone 162c (31) and β-actin/HRP (clone 
AC15, Abcam). HRP-conjugated goat polyclonal 
anti-mouse IgG (P0447, Dako) were used as 
secondary antibodies. 
 
RNA preparation 
Cells were harvested and total RNA was prepared 
using mirVanaTM miRNA isolation kit (AM1560; 
Life Technologies) according to the 
manufacturer’s protocol. Genomic DNA was 
removed from RNA samples using TURBO DNA-
freeTM Kit (AM1907; Life Technologies) 
according to the manufacturer’s protocol. 
 
RNA seq library preparation and sequencing 
Total RNA was subjected to poly-A selection and 
100bp paired-end sequences for the poly-A+ 
fraction were generated on the Illumina 
HiSeq2000. Library preparation was performed 
using Magnetic mRNA Isolation kit (S1550S; 
New England Biolab) followed by NEBNext 
mRNA Sample Prep kit for Illumina (E6110; New 
England Biolab). 
 
RNA-seq data analysis 
RNA seq ‘reads’ were aligned to the human 
reference genome (hg19) using Tophat2 (version 
2.0.10). An average of 92.9 (range 88.1M to 
109.0M) reads were mapped, representing an 
average 93.5% (range 92.1% to 94.6%). 
Quantification over gene models present in 
Ensembl (build 72) was performed using 
gtf2table.py from the CGAT toolkit (60) and 
average exon counts were used for downstream 
analysis. Differential expression analysis was 
performed on each condition contrast using DESeq 
from R/Bioconductor (version 1.10.1) and 
differentially expressed genes were identified at a 
false discovery rate (FDR) of < 0.05 and fold 
change > 2. Sequence data have been deposited at 
the EBI ENA with the accession number E-
MTAB-4264.  
 
Enrichment for HIF binding and HIF siRNA 
gene sets 
To investigate overlap between gene clusters 
identified in our RNA-seq data and HIF binding 
and genes regulated by HIF, we used reported 
genome-wide mapping of HIF-binding sites by 
CHIP-seq. Nearest coding gene neighbours of 
HIF1α and HIF2α binding sites were obtained 
from Supplementary Tables 1 and 2 as reported in 
Schodel et al (40). Raw RNA-seq data for HIF1α, 
HIF2α and HIF1α + HIF2α, along with scrambled 
siRNA control data, were downloaded from the 
European Nucleotide Archive (ENA) with 
accession number E-MTAB-1994, as reported in 
(41). These data were processed in the same way 
as reported here for our primary RNA-seq data 
sets; differentially expressed genes were identified 
for each siRNA vs. the scrambled control. For 
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each cluster and HIF binding and siRNA gene set 
combination, we assessed the number of 
overlapping genes. We derived an empirical 
significance value by generating an expected 
overlap distribution for each combination by 
taking a random set of genes of equal length to the 
cluster gene set and taking the overlap in 1000 
samples. We calculated the p-value as the fraction 
of times we observed a greater than or equal 
overlap to the observed cluster vs. gene set 
overlap.  
 
Microarray 
RNA samples were processed by the Oxford 
Genomics Centre, Wellcome Trust Centre for 
Human Genetics, Oxford for quality control 
analysis, amplification and hybridisation on 
HumanHT-12 v4.0 Expression BeadChip 
(Illumina, San Diego, USA). Microarray analysis 
was performed using the LIMMA package (61) in 
R (version 2.15.2). Signal intensities generated 
using the BeadStudio (Illumina Inc.) software 
were normalised for between-array differences 
using quantile normalisation and log2 
transformation. Differentially expressed probes 
between each condition and normoxia were called 
using an empirical Bayes procedure implemented 
in LIMMA. A total of 21507 probes corresponding 
to 17426 unique genes were analysed. The 
microarray data are available at the EBI 
arrayExpress under the accession number E-
MTAB-4300. 
 
Quantitative real time PCR (qRT-PCR) 
Total RNA preparations (after genomic DNA 
removal) were reverse-transcribed to cDNA using 
the High Capacity cDNA kit (4374966; Life 
Technologies) according to the manufacturer’s 
protocol. SYBR Green-based qRT-PCR was then 
performed on the synthesised cDNA using Fast 
SYBR Green Master Mix (4385612, Life 
Technologies) on an Applied Biosystem 
StepOnePlus thermocycler (Life Technologies). β-
actin was used for normalisation and fold change 
was determined using the ∆∆Ct method. 
Sequences of primers used: ACTB_F: 
GCTGTGCTACGTCGCCCTG; ACTB_R: 
GGAGGAGCTGGAAGCAGCC; ADM_F: 
TTGGCAGATCACTCTCTTAG; ADM_R: 
TTCCACTTCTTTCGAAACTC; ANKRD37_F: 
TGTGTTGCCGTGCTCAGACAGA; 
ANKRD37_R: 
ACCCACGTGACATCAGCACTTC; BNIP3_F: 
TGAGTCTGGACGGAGTAGCTC; BNIP3_R: 
CCCTGTTGGTATCTTGTGGTGT; CA9_F: 
AAATCGCTGAGGAAGGCTCAGA; CA9_R: 
CAGGGCGGTGTAGTCAGAGA; EGLN3_F: 
CACGAAGTGCAGCCCTCTTA; EGLN3_R: 
TTGGCTTCTGCCCTTTCTTCA; HIF1ΑN_F: 
CTGTGAACTTCTGGTATAAGG; HIF1ΑN_R: 
CTCATTATGGCCACTTTCTG; HK2_F: 
CCCCTGCCACCAGACTAAACTA; HK2_R: 
CAAAGTCCCCTCTCCTCTGGAT; LDHA_F: 
CACCATGATTAAGGGTCTTTAC; LDHA_R: 
AGGTCTGAGATTCCATTCTG; PPFIA4_F: 
CGGCGGCTAAAGAAGAAACAC; PPFIA4_R: 
CAGGAGACCACAGTAGGACCAT; SOX9_F: 
CTCTGGAGACTTCTGAACG; SOX9_R: 
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AGATGTGCGTCTGCTC; VLDLR_F: 
GGAACCGGGAGAAAAGCCAAAT; 
VLDLR_R: CCCCATCACATTTCCACAACAG. 
 
FIH siRNA and transfection 
Subconfluent MCF-7 cells were trypsinised and 
resuspended in Dulbecco’s Modified Eagle 
Medium (DMEM) without antibiotics before being 
reverse-transfected with 5 nM final concentration 
of SilencerTM Select Pre-Designed & Validated 
FIH siRNA (s31197, Life Technologies) using 
Opti-MEM I Reduced Serum Medium (51985-
034; Life Technologies) and Lipofectamine 
RNAiMAX (13778150; Life Technologies) 
according to manufacturer’s protocol. 48 h 
following the transfection, MCF-7 cells were 
incubated under hypoxia (0.5% O2) in In vivo2 400 
hypoxic workstation (Ruskin Technologies) or 
subjected to the indicated inhibitor treatment for 
16 h. 
 
In vitro hydroxylation assays 
Inhibition assays for PHD1-3 were performed by 
matrix-assisted laser desorption/ionisation time-of-
flight mass spectrometry (MALDI-TOF MS) using 
a Waters® Micromass® MALDI micro MX™ 
mass spectrometer via a modified version of the 
reported procedure (62). Dose responses were 
assessed by incubation of PHD isoforms (1 µM) 
with increasing inhibitor concentrations (0.03 µM, 
0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM, 30 µM, 100 
µM) in the presence of Fe(II) (50 µM), 2OG (10 
µM), ascorbate (4 mM) and a 19-mer CODD-
peptide (10 µM; DLDLEMLAPYIPMDDDFQL-
NH2) in 50 mM Tris (pH 7.5) at 37 °C. Reactions 
were quenched with formic acid (1 % v/v) at a 
time-point within the linear region of enzymatic 
activity. Hydroxylation levels were quantified 
using MassLynx™ V4.0 and IC50 values were 
determined with GraphPad Prism®. Inhibition 
assays for JMJD1A (KDM3A), JMJD2E 
(KDM4E), JMJD3 (KDM6B) and FBXL11 
(KDM2A) were carried out as previously 
described (33).  
 
Protein expression and purification 
PHD1 full-length enzyme with a N-terminal MBP-
tag was expressed in E. coli BL21(DE3) cells. The 
cultures in 2TY medium were grown to OD600 of 
0.6-0.8, then induced with 0.5 mM isopropyl-beta-
D-thiogalactopyranoside (IPTG); growth was 
continued at 37 °C for 4h. Cells were lysed by 
sonication in 20 mM Tris-HCl (pH 7.5), 200 mM 
NaCl, and the crude tagged PHD1 was purified 
over an amylose-affinity column according to the 
manufacturer’s protocol for pMAL™ Protein 
Fusion & Purification System (New England 
Biolabs). 
PHD2181-426 with an N-terminal His6-tag was 
produced as described (63). Recombinant PHD3 
full-length enzyme with an N-terminal 
thioredoxin-tag and His6-tag was produced in E. 
coli BL21(DE3) cells. Cell cultures in 2TY 
medium were grown to OD600 of 0.6-0.8, then 
induced with 0.05 mM IPTG; growth was 
continued overnight at 18 °C. Cells were lysed by 
sonication in 20 mM Tris-HCl (pH 7.5), 500 mM 
NaCl, 5 mM imidazole, and the crude tagged 
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PHD3 was purified via affinity chromatography 
over a His-trap column (as previously reported by 
Chowdhury et al. (63)).  
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FOOTNOTES 
4 Abbreviations used: 
2-OG, 2-oxoglutarate;  
BIQ, bicyclic isoquinoline; 
BNS, bicyclic naphthalenylsulfonyl; 
CBP, CREB binding protein; 
CODD, C-terminal oxygen-dependent degradation 
domains; 
CTAD, C-terminal transactivation domain; 
DM-NOFD, dimethyl N-oxalyl-D-phenylalanine; 
DMOG: dimethyl N-oxalyl glycine; 
DMSO, dimethyl sulfoxide; 
FDR, false discovery rate;  
FIH, factor inhibiting HIF; 
FPKM, fragments per kilobase of transcripts per 
million mapped reads; 
HIF, hypoxia inducible factor; 
HyAsn803, HIF1α hydroxyasparagine-803. 
IC50, half-maximal inhibitory concentration; 
KDM, histone N-methyl lysine demethylase; 
NOG: N-oxalyl glycine; 
NODD, N-terminal oxygen-dependent degradation 
domains; 
NTAD, N-terminal transactivation domain; 
p300, E1A binding protein p300; 
PHD, prolyl hydroxylase domain; 
PHI, HIF prolyl hydroxylase domain inhibitor; 
VHL, von Hippel-Lindau protein. 
 
FIGURE LEGENDS 
Figure 1 Upregulation of HIFα isoforms by the 
HIF hydroxylases. (A) The hypoxia HIF sensing 
pathway, showing the role of the HIF prolyl-
hydroxylases (PHDs) and asparaginyl-
hydroxylases (FIH). Prolyl hydroxylation occurs at 
either or both of the N- or C-terminal oxygen 
degradation domain (NODD or CODD). Each 
PHD/FIH catalysed reaction is coupled to the 
conversion of 2OG and O2 into succinate and 
carbon dioxide (CO2). (B) Chemical structures of 
IOX2, BNS and BIQ (collectively referred to as 
the PHIs) and DM-NOFD (FIH inhibitor) used in 
this work. (C) Inhibition curves for BIQ (top), 
IOX2 (middle) and NOG (bottom) and their 
respective IC50 values as determined from in vitro 
hyd roxylation assays for recombinant PHD1 
(left), PHD2 (middle) and PHD3 (right). Each 
datapoint represents average signal ± standard 
deviation (n=3). (D) Immunoblots showing 
upregulation of HIF1α and HIF2α proteins in 
MCF-7 cells after 16 h treatment with the 
inhibitors, in comparison to hypoxic treatment 
(0.5% O2). Note the lack of inhibition of HIF1α 
asparaginyl-hydroxylation by the more selective 
HIF PHIs, in comparison to the broad spectrum 
2OG-oxygenase inhibitor DMOG. For 
experimental details, see the Materials and 
Methods section. NOG: N-oxalyl glycine, 
DMOG: dimethyl N-oxalyl glycine, BNS: bicyclic 
naphthalenylsulfonyl, BIQ: bicyclic isoquinoline, 
NOFD: N-oxalyl-D-phenylalanine, DM-NOFD, 
dimethyl N-oxalyl-D-phenylalanine, DMSO: 
dimethyl sulfoxide. 
 
Figure 2 DMOG better mimics the 
transcriptional response to hypoxia than 
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selective PHI in MCF7 cells. (A) Hierarchical 
clustering (Manhattan distance, Ward’s linkage) of 
samples based on FPKM values of 13,351 genes. 
Clustering was performed using the pvclust 
package in R-3.1.3. The numbers represent the 
bootstrap probabilities (BP) based on 1000 
bootstrap resamples. Values >95% represent 
highly supported clusters. (B) Hierarchical 
clustering (Manhattan distance, Ward’s linkage) of 
genes and samples based on FPKM values of 1081 
hypoxia-regulated genes. The left panel of the 
heatmap represents cluster assignments of genes 
based on k-means clustering with k=4 using the 
kmeans function in R (v3.1.3). (C) The overlap of 
genes that were called as differentially regulated 
between each experimental condition and 
normoxia. (D) Immunoblots showing the time-
course of HIFα induction in MCF-7 cells by IOX2, 
one of the selective PHIs in comparison to hypoxic 
treatment. (E) Overlap of HIF1α and HIF2α 
binding and gene clusters. A published list of 
genes annotated as nearest neighbours to HIF 
binding sites (40) was intersected with each cluster 
of genes from RNA-seq analysis. The proportion 
overlapping are plotted. Significance of the 
overlap was determined using a sampling 
procedure described in Materials and Methods. 
(G) Overlap of HIF1α and HIF2α regulated genes 
by siRNA. Publically available RNA-seq data for 
siRNAs against HIF1α, HIF2α or both were 
analysed and the overlap between genes 
downregulated upon knockdown. 
DMOG: dimethyl N-oxalyl glycine, BNS: bicyclic 
naphthalenylsulfonyl, BIQ: bicyclic isoquinoline, 
DMSO: dimethyl sulfoxide, HyAsn803: HIF1α 
hydroxyasparagine-803, l.e.: long exposure. 
 
Figure 3 Hypoxia-regulated genes in response 
to combined PHD and FIH inhibition. (A) 
Immunoblots showing the inhibition of HIF1α 
asparaginyl-hydroxylation using either small 
molecule FIH inhibitor (DM-NOFD), siRNA-
mediated FIH knockdown, or both in MCF-7 cells. 
(B-C) Correlation of fold changes observed in 
hypoxia versus normoxia between RNA-seq and 
microarray analyses and the corresponding overlap 
of genes identified as being differentially 
expressed in each analysis (FDR < 0.05) (D-E) 
Correlation of fold changes observed in DMOG 
versus normoxia between RNA-seq and 
microarray analyses and the corresponding overlap 
of genes identified as being differentially 
expressed in each analysis (FDR < 0.05). (F-G) 
Correlation of fold changes observed in IOX2 
versus normoxia between RNA-seq and 
microarray analyses and the corresponding overlap 
of genes called as differentially expressed in each 
analysis (FDR < 0.05). (H) Transcriptional profile 
of genes in the microarray analysis that were 
assigned to cluster 2 using RNA-seq data, i.e. 
genes upregulated in all conditions. Labelled are 
those genes that were verified using qPCR. (I) 
Transcriptional profile of genes in the microarray 
analysis that were assigned to cluster 3 using 
RNA-seq data i.e. genes upregulated 
predominantly by DMOG and hypoxia, but not 
PHI. The genes that were verified using qRT-PCR 
are labelled. 
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DMOG: dimethyl N-oxalyl glycine, BNS: bicyclic 
naphthalenylsulfonyl, BIQ: bicyclic isoquinoline, 
DM-NOFD, dimethyl N-oxalyl-D-phenylalanine, 
DMSO: dimethyl sulfoxide, HyAsn803: HIF1α 
hydroxyasparagine-803, l.e.: long exposure. 
 
Figure 4 Hypoxia upregulated genes have 
different dependencies on the PHDs and FIH. 
(A) RNA-seq, microarray and qRT-PCR analyses 
showing an exemplary subset of hypoxia-induced 
genes (BNIP3, LDHA, AK4, PPFIA4) that are 
substantially induced by DMOG and the PHIs. (B) 
RNA-seq, microarray and qRT-PCR analyses 
reveal that a subset of hypoxia-induced genes 
(CA9, ADM, EGLN3, HK2) with comparable 
induction by DMOG but not by the selective PHD 
inhibitors (PHI). Simultaneous use of a PHI and an 
FIH inhibitor/siRNA induce these genes to a level 
comparable to that observed in hypoxia. (C) RNA-
seq, microarray and qRT-PCR analyses reveal that 
a subset of hypoxia-induced genes (SOX9, 
ANKRD37) that are not induced or induced at a 
lower level by the simultaneous inhibition of the 
PHDs and FIH. (D) qRT-PCR analyses showing 
the time-dependent induction of (left) SOX9 and 
(right) ANKRD37 with the inhibition of the PHDs, 
or both the PHDs and FIH in comparison to 
hypoxia. 
HyAsn803: HIF1α hydroxyasparagine-803, 
IOX2FIHi: 250 µM IOX2 + 1 mM DM-NOFD + 5 
nM FIH siRNA, IOX2 + DM-NOFD: 250 µM 
IOX2 + 1 mM DM-NOFD, BNIP3: 
BCL2/adenovirus E1B 19 kDa protein-interacting 
protein 3, LDHA: L-lactate dehydrogenase A 
chain, VLDLR: Very low-density lipoprotein 
receptor, PPFIA4: Liprin-alpha-4, CA9: Carbonic 
anhydrase 9, ADM: Adrenomedullin, EGLN3: 
Prolyl hydroxylase domain-containing protein 3, 
HK2: Hexokinase-2, SOX9: SRY (sex determining 
region Y)-box 9, ANKRD37: Ankyrin repeat 
domain-containing protein 37, FPKM: fragments 
per kilobase of transcripts per million mapped 
reads. Each barplot represents n=2 per condition. 
 
Figure 5 Dependency of hypoxia upregulated 
genes on the PHDs and FIH is context-
dependent. (A) Comparison of the induction of 
selected hypoxia upregulated genes in U2OS, 
Hep3B and HeLa cells with the inhibition of the 
PHDs, or both the PHDs and FIH in comparison to 
hypoxia. Note the differences in results for some 
of the same genes in different cell types. Data 
shown are representative of three independent 
experiments. (B) Immunoblots showing the 
different levels of HIF1α, HyAsn803, FIH, PHD1, 
PHD2 and PHD3 under normoxia, hypoxia (0.5% 
O2) or with the treatment of HIF hydroxylase 
inhibitors  in MCF-7, U2OS and Hep3B cells. 
HyAsn803: HIF1α hydroxyasparagine-803, IOX2 
+ DM-NOFD: 250 µM IOX2 + 1 mM DM-NOFD. 
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